Skip to content
  • Home
  • Visit our other Journals
    • VJHemOnc
    • VJOncology
    • VJNeurology
    • VJDementia
    • VJHemOnc-E
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

CRS

An insight into novel third-generation TLR2 co-stimulatory CAR-T cells 1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
Targetting cancer with allogeneic NK cell therapies 3:05
Targetting cancer with allogeneic NK cell therapies
James Trager • 10 Mar 2021
Management of CAR-T related side effects 1:50
Management of CAR-T related side effects
Ibrahim Yakoub-Agha • 4 Feb 2021
Cytopenias post-CAR T-cell therapy 4:10
Cytopenias post-CAR T-cell therapy
Ibrahim Yakoub-Agha • 4 Feb 2021
Infectious complications after CAR T-cell therapy 2:02
Infectious complications after CAR T-cell therapy
Joshua Hill • 10 Feb 2021
CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias 3:50
CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias
Marion Subklewe • 11 Feb 2021
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy